EVIRAPINE, USED TO PREvent mother-to-child human immunodeficiency virus (HIV) transmission, selects drug-resistant viral mutations among a large proportion of HIVinfected infants 1,2 and is associated with reduced viral suppression when nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy is initiated. 3 A trial comparing nevirapine-based therapy to protease inhibitor (PI)-based therapy among nevirapine-exposed infants was terminated early when reduced viral suppression was observed in the nevirapine-based therapy group, 4 consistent with an adult study. 5 Current guidelines for nevirapine-exposed infants advise that treatment be initiated with regimens based on ritonavir-boosted lopinavir. 6 There are many limitations of continuing to use PI-based regimens in-definitely in young children. These include its unpleasant taste, which poses adherence challenges for children too Author Affiliations are listed at the end of this article.